Compared to the other c-Abl inhibitors, low dose nilotinib is more advantageous for penetrating the blood brain barrier (BBB) and degrades α-synuclein through a process of autophagy in PD models [14-17]. The gene discussed is ABL1; the disease is Parkinson disease.